• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞角蛋白 5 和细胞角蛋白 20 与 Ta 非肌肉浸润性膀胱癌的肿瘤分级呈负相关。

Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.

机构信息

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Organ Systems, KU Leuven, Leuven, Belgium.

出版信息

J Cell Mol Med. 2021 Aug;25(16):7890-7900. doi: 10.1111/jcmm.16712. Epub 2021 Jun 29.

DOI:10.1111/jcmm.16712
PMID:34184816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8358875/
Abstract

Cytokeratin 5 is a marker of basal molecular subtypes of muscle-invasive bladder cancer (MIBC), which correlates with worse overall survival compared to luminal subtypes. Our observations have not confirmed CK5 as a marker of high-grade (HG) disease in Ta non-muscle-invasive bladder cancer (NMIBC). Therefore, to understand the basal-luminal immunohistochemistry profile in Ta NMIBC, we performed immunohistochemistry for CK5, P40, P63 (basal), GATA3 and CK20 (luminal) and studied the correlation with HG and clinical outcome in 109 patients with Ta NMIBC. HG and low-grade (LG) diseases were scored in each patient. Four different CK5 patterns were evaluated: absent (median 41.3%), normal (72.5%), rising (84.4%) and full thickness (23.9%). The median percentage of GATA3 was 100%. HG disease and CK5 expression and rising CK5 pattern had a significant inverse correlation, whereas HG disease and CK20 expression had a significant positive correlation. We also found a significant inverse correlation between CK5 expression and CK20 expression. Quantitative PCR confirmed that the presence of CK5 correlated with up-regulation of CK5 RNA. None of the markers could differentiate patients with regard to clinical outcome. Our results suggest a role for CK5 and CK20 in differentiating between LG and HG disease in Ta NMIBC.

摘要

细胞角蛋白 5 是肌层浸润性膀胱癌(MIBC)的基底分子亚型标志物,与 luminal 亚型相比,其总体生存率更差。我们的观察结果并未证实 CK5 是 Ta 非肌层浸润性膀胱癌(NMIBC)中高级别(HG)疾病的标志物。因此,为了了解 Ta NMIBC 中的基底-亮细胞免疫组织化学特征,我们对 CK5、P40、P63(基底)、GATA3 和 CK20(亮细胞)进行了免疫组织化学染色,并在 109 例 Ta NMIBC 患者中研究了它们与 HG 和临床结果的相关性。对每位患者进行 HG 和低级别(LG)疾病评分。评估了四种不同的 CK5 模式:缺失(中位数 41.3%)、正常(72.5%)、上升(84.4%)和全层(23.9%)。GATA3 的中位数百分比为 100%。HG 疾病和 CK5 表达以及上升的 CK5 模式与显著负相关,而 HG 疾病和 CK20 表达与显著正相关。我们还发现 CK5 表达与 CK20 表达之间存在显著的负相关。定量 PCR 证实 CK5 的存在与 CK5 RNA 的上调相关。没有一种标志物可以区分患者的临床结果。我们的结果表明 CK5 和 CK20 在区分 Ta NMIBC 中的 LG 和 HG 疾病方面发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/b4bec605bca5/JCMM-25-7890-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/d0b3f149ef5b/JCMM-25-7890-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/ef49c5a466c6/JCMM-25-7890-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/9f58113e18cd/JCMM-25-7890-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/b4bec605bca5/JCMM-25-7890-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/d0b3f149ef5b/JCMM-25-7890-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/ef49c5a466c6/JCMM-25-7890-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/9f58113e18cd/JCMM-25-7890-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6558/8358875/b4bec605bca5/JCMM-25-7890-g001.jpg

相似文献

1
Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.细胞角蛋白 5 和细胞角蛋白 20 与 Ta 非肌肉浸润性膀胱癌的肿瘤分级呈负相关。
J Cell Mol Med. 2021 Aug;25(16):7890-7900. doi: 10.1111/jcmm.16712. Epub 2021 Jun 29.
2
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.预测非肌肉浸润性(Ta/T1)膀胱癌的结局:基于腔面/基底表型的分子分级的作用。
Virchows Arch. 2019 Oct;475(4):445-455. doi: 10.1007/s00428-019-02593-x. Epub 2019 Jun 25.
3
Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.使用 Gata3 及细胞角蛋白 5/6、14 和 20 的有限免疫组织化学组合对肌层浸润性尿路上皮癌进行预后分层。
Ann Diagn Pathol. 2019 Dec;43:151397. doi: 10.1016/j.anndiagpath.2019.08.001. Epub 2019 Aug 3.
4
Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.使用细胞角蛋白20(CK20)和细胞角蛋白5(CK5)进行免疫组织化学亚型分类可识别预后不良的上尿路尿路上皮癌。
PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. eCollection 2017.
5
Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.免疫组织化学染色分析细胞角蛋白(CK)5/6、CD44 和 CK20 作为非肌肉浸润性乳头状上尿路尿路上皮癌的预后生物标志物。
Histopathology. 2019 Feb;74(3):483-493. doi: 10.1111/his.13763. Epub 2018 Dec 2.
6
Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.膀胱非肌肉浸润性尿路上皮癌中基底和腔面标志物的免疫组织化学评估。
Virchows Arch. 2019 Sep;475(3):349-356. doi: 10.1007/s00428-019-02618-5. Epub 2019 Jul 12.
7
Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.基于 GATA3、CK20、CK5/6 和 CK14 免疫组化表达的亚型对肌层浸润性膀胱癌根治性膀胱切除术后生存的影响。
Sci Rep. 2021 Oct 27;11(1):21186. doi: 10.1038/s41598-021-00628-5.
8
In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.在pT1期非肌层浸润性膀胱癌(NMIBC)中,高KRT20和低KRT5 mRNA表达可识别管腔亚型,并预测复发和生存情况。
Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10.
9
Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.GATA3、细胞角蛋白 20、细胞角蛋白 5/6 和 p53 表达在肌层浸润性膀胱癌中的生物学意义。
PLoS One. 2019 Aug 30;14(8):e0221785. doi: 10.1371/journal.pone.0221785. eCollection 2019.
10
Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?三标志物免疫组化评估肌层浸润性膀胱癌:是否有预后意义?
Cancer Rep (Hoboken). 2021 Apr;4(2):e1313. doi: 10.1002/cnr2.1313. Epub 2021 Feb 4.

引用本文的文献

1
Fibroblast Activation Protein-α and the Immune Landscape: Unraveling T1 Non-muscle-invasive Bladder Cancer Progression.成纤维细胞活化蛋白-α与免疫格局:揭示T1期非肌层浸润性膀胱癌的进展
Eur Urol Open Sci. 2024 Jul 1;66:67-74. doi: 10.1016/j.euros.2024.06.011. eCollection 2024 Aug.
2
Clinicopathological Features and Survival Analysis in Molecular Subtypes of Muscle-Invasive Bladder Cancer.肌肉浸润性膀胱癌分子亚型的临床病理特征和生存分析。
Int J Mol Sci. 2023 Apr 1;24(7):6610. doi: 10.3390/ijms24076610.
3
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.

本文引用的文献

1
Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression.膀胱癌分子分类的临床应用实用性和上皮-间充质转化的附加价值:波形蛋白表达的预后价值。
J Transl Med. 2020 Aug 5;18(1):303. doi: 10.1186/s12967-020-02475-w.
2
ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.膀胱癌中 ΔNp63 转录本缺失构成 TaT1 患者治疗后复发和进展的独立分子预测因子。
J Cancer Res Clin Oncol. 2019 Dec;145(12):3075-3087. doi: 10.1007/s00432-019-03028-5. Epub 2019 Oct 8.
3
我们是否准备好在临床实践中实施膀胱癌的分子亚型分类?第 1 部分:一般问题和标志物表达。
Int J Mol Sci. 2022 Jul 15;23(14):7819. doi: 10.3390/ijms23147819.
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
肌肉浸润性膀胱癌的共识分子分类。
Eur Urol. 2020 Apr;77(4):420-433. doi: 10.1016/j.eururo.2019.09.006. Epub 2019 Sep 26.
4
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌(TaT1 和原位癌)指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
5
Molecular pathology of the luminal class of urothelial tumors.尿路上皮肿瘤 luminal 型的分子病理学。
J Pathol. 2019 Nov;249(3):308-318. doi: 10.1002/path.5318. Epub 2019 Aug 27.
6
Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.免疫组织化学染色分析细胞角蛋白(CK)5/6、CD44 和 CK20 作为非肌肉浸润性乳头状上尿路尿路上皮癌的预后生物标志物。
Histopathology. 2019 Feb;74(3):483-493. doi: 10.1111/his.13763. Epub 2018 Dec 2.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的综合分子特征分析
Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5.
9
A double dealing tale of p63: an oncogene or a tumor suppressor.p63 双重欺骗的故事:癌基因还是肿瘤抑制因子。
Cell Mol Life Sci. 2018 Mar;75(6):965-973. doi: 10.1007/s00018-017-2666-y. Epub 2017 Oct 3.
10
Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.使用细胞角蛋白20(CK20)和细胞角蛋白5(CK5)进行免疫组织化学亚型分类可识别预后不良的上尿路尿路上皮癌。
PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. eCollection 2017.